A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Patients with diagnosis of hereditary angioedema (HAE) who have a moderate to very severe coetaneous or abdominal HAE attack will receive a subcutaneous injection of Icatibant or placebo. Patients will be closely monitored for eight hours. Patient will return to the clinic for five follow-up visits.

You may be eligible to participate in this study if you:

• Are 18 years of age or older
• Had a Diagnosis of HAE
• Have never been treated with Icatibant prior to study
• Are not pregnant or breastfeeding

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.